MRS 1523 (CAS 212329-37-8)
See product citations (2)
QUICK LINKS
MRS 1523 is a selective and potent antagonist of the P2Y1 receptor, which is a G protein-coupled receptor for ADP. It functions by competitively inhibiting the binding of ADP to the P2Y1 receptor, thereby blocking downstream signaling pathways mediated by this receptor. Mrs 1523′s mechanism of action involves targeting the P2Y1 receptor and preventing its activation by ADP, thereby interfering with intracellular calcium mobilization and other cellular responses mediated by this receptor. By blocking the P2Y1 receptor, MRS 1523 can modulate platelet aggregation, vascular smooth muscle contraction, and other physiological processes regulated by this receptor. Mrs 1523′s functional role in experimental applications involves studying the specific effects of P2Y1 receptor antagonism on cellular and physiological processes, providing insights into the role of this receptor in various biological pathways.
MRS 1523 (CAS 212329-37-8) References
- Characterization of adenosine receptor(s) involved in adenosine-induced bronchoconstriction in an allergic mouse model. | Fan, M., et al. 2003. Am J Physiol Lung Cell Mol Physiol. 284: L1012-9. PMID: 12533441
- Postconditioning reduces infarct size via adenosine receptor activation by endogenous adenosine. | Kin, H., et al. 2005. Cardiovasc Res. 67: 124-33. PMID: 15949476
- Cl-IB-MECA inhibits human thyroid cancer cell proliferation independently of A3 adenosine receptor activation. | Morello, S., et al. 2008. Cancer Biol Ther. 7: 278-84. PMID: 18059189
- Stimulation of the adenosine A3 receptor reverses vascular hyporeactivity after hemorrhagic shock in rats. | Zhou, R., et al. 2010. Acta Pharmacol Sin. 31: 413-20. PMID: 20348945
- P-glycoprotein mediates resistance to A3 adenosine receptor agonist 2-chloro-N6-(3-iodobenzyl)-adenosine-5'-n-methyluronamide in human leukemia cells. | Mlejnek, P., et al. 2012. J Cell Physiol. 227: 676-85. PMID: 21520073
- Hide and seek: a comparative autoradiographic in vitro investigation of the adenosine A3 receptor. | Haeusler, D., et al. 2015. Eur J Nucl Med Mol Imaging. 42: 928-39. PMID: 25739834
- Adenosine A3 receptor activation inhibits pronociceptive N-type Ca2+ currents and cell excitability in dorsal root ganglion neurons. | Coppi, E., et al. 2019. Pain. 160: 1103-1118. PMID: 31008816
- LJ529 attenuates mast cell-related inflammation via A3R-PKCε-ALDH2 pathway after subarachnoid hemorrhage in rats. | Zhang, T., et al. 2021. Exp Neurol. 340: 113686. PMID: 33713658
- Adenosine receptor antagonists: Recent advances and therapeutic perspective. | Saini, A., et al. 2022. Eur J Med Chem. 227: 113907. PMID: 34695776
- Pharmacological characterization of DPTN and other selective A3 adenosine receptor antagonists. | Gao, ZG., et al. 2021. Purinergic Signal. 17: 737-746. PMID: 34713378
- Role of Adenosine Kinase in Sphingosine-1-Phosphate Receptor 1-Induced Mechano-Hypersensitivities. | Lauro, F., et al. 2022. Cell Mol Neurobiol. 42: 2909-2918. PMID: 34773542
- A3 adenosine receptor agonist IB-MECA reverses chronic cerebral ischemia-induced inhibitory avoidance memory deficit. | Cheng, P., et al. 2022. Eur J Pharmacol. 921: 174874. PMID: 35278404
- Therapeutic Potential of Highly Selective A3 Adenosine Receptor Ligands in the Central and Peripheral Nervous System. | Coppi, E., et al. 2022. Molecules. 27: PMID: 35335254
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
MRS 1523, 5 mg | sc-253057 | 5 mg | $254.00 | |||
MRS 1523, 25 mg | sc-253057A | 25 mg | $978.00 |